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AB S T R A C T 
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: 
To assess the efficacy and acceptability of pharmacological interventions for preventing post-traumatic stress 
disorder (PTSD) in adults exposed to a traumatic event and to generate a clinically useful ranking of 
pharmacological interventions according to their efficacy and acceptability by performing a network meta-
analysis. 
 
B A C K G R O U N D 
Description of the condition 
Post-traumatic stress disorder (PTSD) is a severe and debilitating disorder which may develop in people exposed 
to traumatic events. Up to 80% of the adult population in the USA have been exposed to a traumatic event 
eligible for diagnosis of PTSD (Breslau 2012), and estimates are similar for Europe (de Vries 2009). The lifetime 
prevalence of PTSD is estimated at 6.8% (Kessler 2005), and the 12-month prevalence at 3.5% (Kessler 2005a). 
General prevalence rates are higher in displaced populations (Bogic 2015; Turrini 2017), and populations 
exposed to conflict (Steel 2009). 
 
According to the Diagnostic and Statistical Manual of Mental Disorders, FiJh Edition (DSM-5), traumatic events 
eligible for the diagnosis "include, but are not limited to, exposure to war as a combatant or civilian, threatened 
or actual physical assault, threatened or actual sexual violence, being kidnapped, being taken hostage, terrorist 
attack, torture, incarceration as a prisoner of war, natural or human-made disasters, and severe motor vehicle 
accidents" (APA 2013). As stated by the DSM, this list is not comprehensive and many different traumatic events 
have proved capable of triggering PTSD. For instance, in recent years there has been an increase in reports of 
PTSD in survivors of critical illness, with an estimated prevalence of 25% among this population (Wade 2013). 
With some limitations regarding the nature of the traumatic incident, witnessing a trauma, learning that a 
relative or close friend was exposed to trauma, or being exposed to aversive details about a trauma (as in the 
course of professional duties) may also precipitate PTSD (APA 2013). 
 
Not all individuals exposed to traumatic experiences will develop PTSD. The likelihood of developing PTSD is 
associated with a number of pre-, peri-, and post-traumatic factors (Bisson 2007; Qi 2016), such as history of a 
psychiatric disorder, gender (females are more vulnerable than males), low socioeconomic status, belonging to 
a minority, history of previous trauma, genetic endowment and epigenetic regulation, impaired executive 
functioning and higher emotional reactivity (Aupperle 2012; Guthrie 2005), the severity of the trauma itself, the 
perceived threat to life, whether the event was intentional or unintentional, peritraumatic emotions and 
dissociation (Ozer 2003), and the perceived lack of social support and subsequent life stress (e.g. inability to 
work as a result of the event) (Brewin 2000). 
 
Individuals who develop PTSD following a trauma may experience a wide range of symptoms, which are 
presented in four categories in the DSM-5 (APA 2013). 
 
• Re-experiencing, e.g. recurrent unwanted intrusive memories, distressing dreams, flashbacks, distress at re-
exposure. 
• Avoidance of stimuli associated with the trauma behaviours, e.g. the avoidance of distressing memories 
associated with the traumatic event or avoidance of external reminders. 
• Negative alteration in cognitions and mood associated with the traumatic event, e.g. impairment in recalling 
important aspects of the trauma, negative thoughts and assumptions about oneself or the world, negative 
beliefs about the causes or consequences of the traumatic event, diminished interest or participation in 
significant activities, feeling of detachment from others, inability to experience positive emotions. 
• Arousal symptoms, e.g. hypervigilance, insomnia, irritability, reckless or self-destructive behaviour, problems 
concentrating. The development and maintenance of PTSD is most likely the product of an interaction of 
different factors. Although, current evidence alone cannot explain the complexity underlying PTSD, it is clear 
that multiple and interconnected systems are involved (Kelmendi 2016; Koch 2014; Lee 2016; Pitman 2012), and 
although psychological mechanisms are involved, the disorder has a distinct biological profile (Besnard 2012; 
Nickerson 2013). Appendix 1 presents a summary of the main evidence related to the biological profile of PTSD. 
 
Description of the intervention 
Interventions for preventing the development of PTSD can be divided into two main categories: psychosocial 
and pharmacological. Although this review focuses on the latter, several other publications have examined and 
reviewed the former (Bryant 2007; Forneris 2013; Kearns 2012; Qi 2016; Roberts 2010; Rose 2002). 
 
With respect to pharmacological interventions, drugs belonging to different classes have been examined by 
means of randomised clinical trials, and some reviews have already been published (Amos 2014; Sijbrandij 2015). 
It should be noted that the mechanisms underlying the onset of the disorder are likely to be different from the 
ones maintaining it, and therefore some of the interventions proposed to prevent the onset of the disorder 
differ from the interventions for treatment. 
 
Glucocorticoids are synthetic analogues of hormones involved in immunity and stress response. They can be 
administered in several ways including oral, intravenous and intramuscular. Depending on the purpose, a 
treatment course can last from a single shot to several days. The trials testing steroids for PTSD prevention have 
used either single dose administration or a course of a few days in individuals with severe physical conditions 
(Delahanty 2013; Schelling 2001; Weis 2006). Hydrocortisone, along with some other steroids, is also included 
in the World Health Organization (WHO) Model List of Essential Medicines (WHO 2017), and therefore expected 
to be commonly available in several global contexts. Propranolol is a beta blocker, primarily used for long-term 
treatment in cardiology. Some trials have tested it on a three-week time span for PTSD prevention (Hoge 2012; 
Pitman 2002; Stein 2007). Propranolol is also included in the WHO Model List of Essential Medicines (WHO 
2017). A small trial has investigated a short course of temazepam, which belongs to the class of benzodiazepines 
(common anxiolytic drugs), but found an increase of PTSD onset rather than a decrease (Mellman 2002). 
Recently, there is growing interest in oxytocin, an endogenous hormone involved in sociability and stress 
regulation (Qi 2016), an early trial investigated oxytocin administered in a single intranasal dose (van Zuiden 
2017). Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant, and although this class has 
yielded good results in PTSD treatment, there is uncertainty whether SSRIs are effective in reducing the incidence 
of PTSD (Shalev 2012). Gabapentin, an anticonvulsant with anxiolytic properties and a benign side effect profile, 
has been included in trials of PTSD prevention (Stein 2007). Opioids have been proposed too, for example a large 
retrospective study on USA soldiers with combat injury, found an association between morphine administration 
and lower PTSD incidence (Holbrook 2010). 
 
How the intervention might work 
The biological features of PTSD provide several possible targets for the pharmacological prevention of PTSD. 
Different rationales can explain the efficacy of the investigated drugs. 
 
Glucocorticoids 
Glucocorticoids are involved in both hormonal stress response and memory formation. The hypothalamic-
pituitary-adrenal (HPA) axis has long been a focus in PTSD investigations, and a role for hydrocortisone in 
facilitating extinction learning has been hypothesised (Hruska 2014). In a rodent model a negative association 
has been found between a high dose of steroids and prevalence of PTSD-like behaviour in rats exposed to 
predator scent stress (Cohen 2008), and coherent results were found in a morphological study (Zohar 2011). 
There is also epidemiologic evidence that lower urinary cortisol 
levels in the immediate aftermath of the trauma are associated with future PTSD symptoms (Delahanty 2000; 
McFarlane 1997). 
 
Beta blockers 
A role for adrenaline in the formation of traumatic memories has long been postulated (Pitman 1989). It has 
been argued that a surge in adrenaline concentration in conjunction with trauma, results in a strong emotional 
memory and fear conditioning that could prime PTSD. Later human studies supported a role for the beta 
adrenergic system in memory storing and in the enhanced memories associated with emotional arousal (Cahill 
1994; Southwick 1999), and for propranolol to limit this process (Reist 2001). 
 
Benzodiazepines 
Benzodiazepines are known for reducing arousal and decreasing distress. They have amnesic properties as well, 
mostly inhibiting memory consolidation by impairing long-term episodic storage (Barbee 1993). Despite this, no 
clinical research has found a positive effect for benzodiazepines in the management of traumatic stress 
symptoms (Howlett 2016). 
 
Opioids 
Studies on rodents have found retrograde amnesia properties for morphine, and a possible mechanism for that 
has been proposed via decreasing cyclic adenosine monophosphate or activating Nmethyl- D-aspartate (NMDA) 
receptors in the hippocampus (McNally 2003). Human observational studies support a protective effect for 
morphine (Bryant 2009; Mouthaan 2015). 
 
Oxytocin 
A possible role for oxytocin in the prevention of PTSD is quite a recent approach, which has been proposed on a 
dual assumption theory: a reduction in the amygdala activation and an increase in the activation of the social 
reward brain areas (OlC 2010). Behavioural data on rodents seem to confirm a plausible role for oxytocin (Cohen 
2010). 
 
SSRIs 
SSRI antidepressants are generally considered the first-line pharmacological treatment for PTSD (ISTSS 2018; 
NICE 2018), and might thereby have a putative role in the prevention of the disorder. 
 
Mood stabilisers/anticonvulsants 
As for SSRIs, mood stabilisers/anticonvulsants might have a putative role in PTSD prevention, considering their 
employment as adjuvant/ second-line treatment for anxiety disorders (Van Ameringen 2004). A trial of 
gabapentin has been reported in a previous metaanalysis (Stein 2007). 
 
Omega-3 fatty acid compounds 
Considering their ability to promote neurogenesis in the hippocampus, a key area in memory consolidation and 
fear maintenance, a role has been proposed for omega-3 fatty acids in PTSD prevention (Matsuoka 2011). 
 
Why it is important to do this review 
PTSD represents a heavy burden for the people affected, those around them, health systems and society. 
Findings from the National Vietnam Veterans Longitudinal Study showed that, even after decades, an important 
share of male war veterans have PTSD (4.5%, 95% confidence interval (CI) 1.7 to 7.3) or subthreshold PTSD 
symptoms (6.4%, 95% CI 3.0 to 9.7) (Marmar 2015). Moreover, PTSD is associated with poor general health 
status and unemployment (Zatzick 1997). Most of the evidence regards psychosocial intervention, among which 
trauma-focused and exposure-based therapies are the most promising ones, but many of the studies are 
restricted by small sample sizes and methodological limits (Birur 2017). Despite the abundance of putative 
biological and clinical risk factors for PTSD and various predictive strategies being tested, e.g. supervised 
machine learning (Galatzer-Levy 2014; KarstoJ 2015; Kessler 2014), there is currently no effective way to predict 
who will develop PTSD after a traumatic experience. The biological features of PTSD provide several possible 
targets for the prevention of PTSD, and encouraging results were found in previous meta-analyses (Amos 2014; 
Sijbrandij 2015). Although it would be valuable to have effective interventions for prevention of PTSD, the risk-
to-benefit ratio needs to be carefully assessed, as drugs will entail possible side effects for all of those receiving 
them, and not all of the individuals exposed to a trauma will develop PTSD. 
 
It should be noted that very different kinds of pharmacological interventions have been proposed to prevent 
PTSD onset, but there is a lack of head-to-head trials between them. It is therefore difficult to make an overall 
comparison and establish a hierarchy, both in terms of efficacy, tolerability and acceptability. It therefore 
appears of important value to assess pharmacological interventions to prevent the onset of the condition, 
applying a methodology that allows indirect comparisons. 
 
O B J E C T I V E S 
To assess the efficacy and acceptability of pharmacological interventions for preventing post-traumatic stress 
disorder (PTSD) in adults exposed to a traumatic event and to generate a clinically useful ranking of 
pharmacological interventions according to their efficacy and acceptability by performing a network meta-
analysis. 
 
M E T H O D S 
Criteria for considering studies for this review 
Types of studies 
We will include randomised controlled trials (RCTs) comparing one medication with placebo or one medication 
with another. We will consider trials for inclusion irrespective of language or publication status. For cross-over 
trials, we will consider the data from the first randomised phase only. 
 
Types of participants 
Individuals 
We will include trials on individuals with all of the following characteristics. 
• History of any traumatic event 
• Aged 18 and older 
We will exclude studies targeting symptomatic patients at baseline, as these studies will be included in a second 
parallel review on early interventions, while the present review is on prevention. 
 
Setting 
We will consider trials performed in any type of setting. 
Subset data 
We will include trials in which only a portion of the sample meets the above criteria, provided that the relevant 
data can be gained from the study report or by contacting the authors, and that the effect of randomisation is 
not affected by doing so. 
 
Types of interventions 
The Diagnostic and Statistical Manual of Mental Disorders, FiJh Edition (DSM-5) regards the three months from 
the trauma as a relevant timeframe for symptoms' evolution (APA 2013). We will then consider any 
pharmacological intervention administered with the intention to prevent the onset of post-traumatic stress 
disorder (PTSD) or PTSD symptoms within such a timeframe. We will set no restriction regarding dose, duration, 
administration route of the intervention, 
nor on the presence of any co-medication not related to PTSD prevention. We will not consider trials where the 
experimental medication was used as an augmentation agent to ongoing psychotherapy (e.g. cognitive 
enhancers). 
 
Based on our knowledge of the literature, we expect drugs from the following pharmacological groups to be 
found. 
 
• Glucocorticoids 
• Beta-blockers 
• Benzodiazepines 
• Opioids 
• Other hormones (oxytocin) 
• Selective serotonin reuptake inhibitors (SSRIs) 
• Mood stabilisers/anticonvulsants 
• Omega-3 fatty acid compounds 
 
We assume that any individual that meets the inclusion criteria is, in principle, equally likely to be randomised 
to any of the eligible interventions. 
 
We will include any other pharmacological interventions we might find during the review process and clearly 
report them. We will consider them eligible for the network meta-analysis after assessing their comparability 
with the before mentioned prespecified set of competing interventions, in order to preserve the assumption of 
'jointly randomisable' treatments. 
 
Types of comparison 
We will include studies using both placebo and any active pharmacological comparison. We will not consider 
studies comparing pharmacological interventions with only psychosocial interventions (i.e. with no other 
pharmacological or placebo arm). 
 
We will include studies that meet the above criteria, irrespective of whether they report any of our outcomes of 
interest. 
 
Types of outcome measures 
Primary outcomes 
• PTSD severity (continuous): we will use the mean score on the Clinician-Administered PTSD Scale (CAPS) (Blake 
1995), or the Comprehensive International Diagnostic Interview (CIDI) (WHO 1997), or any other validated rating 
scale to assess symptom severity. 
• Dropouts due to adverse events (dichotomous): we will consider the number of participants who leave the 
assigned arm 
early due to side effects, out of the number of randomised individuals. 
Secondary outcomes 
• PTSD rate (dichotomous): we will consider PTSD rates, as measured by a DSM or International Classification 
of Diseases (ICD) (WHO 1992) diagnosis made with a clinician-administered measure. 
• Depression severity (continuous): we will consider the severity of depressive symptoms, using the score on 
the Hamilton Depression Rating Scale (Hamilton 1960), or the Beck Depression Inventory (Beck 1961), or any 
other validated scale. 
• Anxiety severity (continuous): we will consider the severity of the anxiety symptoms using the score on the 
Covi Anxiety Scale (CAS) (Covi 1984), or the Beck Anxiety Inventory (Beck 1988), or the Spielberger State-Trait 
Anxiety Inventory (Spielberger 1970), or any other validated scale. 
• Functional disability (continuous): we will consider the Sheehan Disability Scale (Sheehan 1996), or any other 
validated 
scale. 
• Quality of life (continuous): we will use the Medical Outcomes Study (MOS) 36-Item Short-Form Health Survey 
(SF-36) (Ware 1992), or any other validated scale to assess quality of life. 
• Dropout for any reason (dichotomous): we will consider the number of participants who leave the assigned 
arm early for any reason, out of the number of randomised individuals. 
 
Hierarchy of outcome measures 
The hierarchy of outcome measure scales will follow the order above. As we expect that clinician-administered 
scales to have been more frequently employed, in case of trials employing validated scales different from the 
before mentioned, for homogeneity reasons we will give priority to clinician-administered scales over self-
reported ones. 
 
Timing of outcome measures 
We will synthesise data at three months follow-up (i.e. 3 months after experiencing trauma), operationalised as 
the time point closest to three months of follow-up (from 2 to 4 months of follow-up). In addition, we will include 
data at study endpoint as a secondary time point. 
 
Search methods for identification of studies Specialised register: the Cochrane Common Mental Disorders 
Controlled Trials Register (CCMDCTR) 
Cochrane Common Mental Disorders (CCMD) maintained a specialised register of randomised controlled trials 
(RCTs), the CCMDCTR, to June 2016. This register contains over 40,000 reference records (reports of RCTs) for 
anxiety and depressive disorders, bipolar disorder, eating disorders, self-harm and other mental disorders within 
the scope of CCMD. The CCMDCTR is a partially studies- based register with > 50% of the reference records 
tagged to 12,600 individually participant, intervention, comparison, outcome (PICO)-coded study records. 
Reports of trials for inclusion 
in the register were collated from (weekly) generic searches of MEDLINE (1950-), Embase (1974-) and PsycINFO 
(1967-), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific 
searches of additional databases. Reports of trials were also sourced from international trial registries, drug 
companies, handsearching of key journals, conference proceedings and other (non-Cochrane) systematic 
reviews and metaanalyses. Details of CCMD's core search strategies (used to identify RCTs) can be found on 
CCMD's website, with an example of the MEDLINE search displayed in Appendix 2. The register fell out-of date 
with the relocation of the group from the University of Bristol to York University in June 2016. 
 
Electronic searches 
CCMDCTR-studies and references register 
We will cross-search the CCMDCTR studies and references register for condition alone, using the following 
terms: 
(PTSD or posttrauma* or post-trauma* or "post trauma*" or "combat disorder*" or "stress disorder*") (all years 
to June 2016). We will screen the search results for any pharmacological intervention (active intervention versus 
placebo or active intervention versus active intervention trials) to prevent the onset of PTSD. 
Biomedical database search 
We will search Ovid MEDLINE, Embase and PsycINFO, Ebsco Published International Literature On Traumatic 
Stress (PILOTS) and the Cochrane Central Register of Controlled Trials (CENTRAL) from 2014 onwards. This is to 
account for the period when the CCMDCTR fell out-of-date. A search has already been conducted by the CCMD 
editorial base (3 March 2018) (Appendix 3). We will screen the results of this search for all relevant 
pharmacological RCTs to prevent the onset of PTSD. 
International trials registers 
We will search for unpublished studies in international trials registers via the World Health Organization's trials 
portal (ICTRP), and the National Institute of Health's trials website (clinicaltrials.gov). See Appendix 4 for search 
strategies on these sources. We will not apply any publication status or language restrictions. We will re-run all 
searches close to publication if the initial search date is greater than 12 months. 
Searching other resources 
We will check the reference list of all included studies and relevant systematic reviews. 
Data collection and analysis 
Selection of studies 
We will import all records obtained via the electronic search, plus the handsearch, into Endnote software 
(EndNote) in order to remove all duplicates. Two review authors (FB and LR) will work in duplicate and 
independently. They will screen all potential papers' titles and abstracts and code them as 'retrieve' or 'not 
retrieve', obtain the full-text publication of the records coded as 'retrieve', and assess inclusion and exclusion 
criteria. Disagreement will be resolved by discussion or, if necessary, by involving a third review author (NM). 
We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics 
of excluded studies' table (Moher 2009). 
Data extraction and management 
Two review authors (FB and LR) working independently and in duplicate will extract data from the included trials. 
We will use a data extraction sheet developed in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions section 7.5 (Higgins 2011). We will collect the following data. 
• First author, year of publication, journal, source of funding, notable conflict of interest of authors, total 
duration of study, number of centres and location. 
• Methodological characteristics of the trial: randomisation, blinding, allocation concealment, number of arms, 
follow-up 
time points. 
• Sample characteristics: study setting, type of trauma, criteria for enrolling, age, gender, number of participants 
randomised to each arm, history of previous trauma. 
• Intervention details: time from the traumatic event to treatment, medication employed, period over which it 
has been administered, dosage range, mean dosage prescribed. 
• Outcomes: time points of outcome assessment, instrument used to assess PTSD symptoms, instrument used 
to assess PTSD rate, instrument used to assess depression symptoms, instrument used to assess anxiety, 
instrument used to assess functional disability, outcome measure employed by original trial (primary and 
secondary), data of continuous (means and standard deviation or standard error if standard deviation is not 
provided) and dichotomous variables of interest, number of total dropouts, number of dropouts due to 
pharmacological side effect, whether the data reflect an intention-to-treat (ITT) model, methods of estimating 
the outcome for participants who dropped out (last observation carried forward (LOCF) or completer/observed 
case (OC) approach, or other). 
 
Assessment of risk of bias in included studies 
Two review authors (FB and LR) working independently and in duplicate will assess risk of bias for each study 
according to the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
2011). Disagreement will be resolved by discussion, or if necessary by involving a third review author (NM). We 
will assess the risk of bias according to the following domains. 
1. Random sequence generation (selection bias) 
2. Allocation concealment (selection bias) 
3. Blinding of participants and personal (performance bias) 
4. Blinding of outcome assessment (detection bias) 
5. Incomplete outcome data (attrition bias) 
6. Selective reporting (reporting bias) 
7. Other bias 
 
We will assess performance, detection and attrition bias on a per outcome basis rather than per study. We will 
rate each source of bias as high, low or unclear. We will provide reasons to justify therating. We will present all 
data regarding risk of bias both graphically and in the text.  
 
Measures of treatment effect  
Dichotomous data  
For dichotomous data, we will calculate risk ratio (RR) estimates and their 95% confidence interval (CI). RRs are 
more easily interpreted than odds ratios (ORs) (Boissel 1999), and as clinicians may risk interpreting ORs as RRs 
(Deeks 2002), this may lead to an over-estimation of the effect. We will calculate the number needed to treat 
to benefit (NNTB).  
Continuous data  
For continuous data, we will calculate the mean differences (MDs)and the 95% CI, where data are measured on 
the same scale. If the studies employed different scales, we will use standardised mean differences (SMDs). The 
trials may report the results either as end point means or using change in mean values from baseline assessment. 
Preference will be given to endpoint measures, given the nature of the review (prevention) and that endpoint 
data are easier to interpret from a clinical point of view. Where sufficient data are reported, we will convert 
change scores into endpoint data using standard formulas reported in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011). We will interpret SMDs according to the following guidelines: 0.2 
represents a small effect,0.5 a moderate effect, and 0.8 a large effect (Cohen 1988). 
Unit of analysis issues 
Crossover trials  
We will consider only the first phase from cross-over trials as the carry over effect cannot be excluded on a 
prevention measure, regardless of appropriate washout times.  
Cluster randomised trials  
If cluster-RCTs are included, but have not appropriately adjusted for the correlation between participants within 
clusters, we will contact trial authors to obtain an estimate of the intra cluster correlation (ICC), or impute using 
estimates from the other included trials or from similar external trials. If imputation of ICCs is required, we will 
conduct sensitivity analyses to examine the impact on estimates. 
Multiple treatment group studies  
For the pair-wise meta-analysis, we will compare each arm with placebo separately and include each pair-wise 
comparison separately. We plan the following means to prevent 'double-counting', in accordance with the 
Cochrane Handbook for Systematic Reviews of Interventions, section 16.5.4 (Higgins 2011): in the case of 
dichotomous variables, we will split the comparison group evenly among the intervention groups, in the case of 
continuous variables, we will only divide the total number of participants and leave the mean and SDs 
unchanged.  
For the network meta-analyses, we will adjust for correlations inherent in multiple-arm trials using standard 
methods (e.g. Dias2013a). 
Dose-ranging studies  
If a study has multiple arms with the same medication administered at different doses or administered for a 
different time length, we will pool these intervention groups into a single one, as recommended by the Cochrane 
Handbook for Systematic Reviews of Interventions, section 16.5.4 (Higgins 2011). 
Dealing with missing data  
As a first measure, we will contact study investigators to obtain missing data. Should this not be effective, we 
will employ the following approaches.  
Dichotomous data 
Where reported, we will use ITT data analysed on a 'once randomised, always randomised' basis. In case of trials 
conducting different imputational strategies, we will give preference to data de-rived from multiple imputation 
or mixed-effects models. For studies that did not perform an ITT analysis, we will assume a negative outcome 
(i.e. onset of PTSD) for individuals lost at follow-up.  
Continuous data  
As above, we will use ITT data where reported, and favour multiple imputation or mixed-effects models where 
different imputationals trategies have been used. In the context of prevention, last observation carried forward 
(LOCF) provides the least conservative option and therefore observed case (OC) data will be preferred. For 
studies not reporting ITT analyses, we will not impute missing data for continuous outcomes, as this usually 
requires access to individual participant data. 
We will report, in the relevant section of the results, if the data employed were based on an imputational 
method and if so, which one.  
Missing statistics 
Where possible, we will calculate SDs when only P values, CIs, standard errors etc. are reported. If this is not be 
possible, we will calculate an arithmetic mean of the SDs of studies using the same scale of the one with missing 
SD, as in Furukawa 2006. 
 
Assessment of heterogeneity 
We will assess heterogeneity by means of: 
•visual inspection on the overlap of the CIs for individual studies in the forest plot; 
•Chi2 test, with a P value set at 0.10 (we presume the number of studies to be small); 
•I2 statistic: in accordance with the suggestion in the Cochrane Handbook for Systematic Reviews of 
Interventions section 9.5.2(Higgins 2011), we will follow a rough guide to interpretation as follows: 0% to 40%: 
might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent 
substantial heterogeneity; 75% to 100%: considerable heterogeneity. We will also take into account magnitude 
and direction of effects. 
 
Assessment of reporting biases 
If more then 10 studies are included per primary outcome, we will: 
•visually inspect the relative funnel plots, test them for asymme-try and investigate possible reasons for funnel 
plot asymmetry; 
•employ Egger's regression test (Egger 1997). 
 
Data synthesis 
Methods for pair-wise meta-analysis  
We will perform standard pair-wise meta-analysis with a random-effects model for every comparison with at 
least two studies, using Review Manager 5 (Review Manager 2014). Given the nature of the data, and the likely 
heterogeneity, we think a random-effects model makes more plausible assumptions. We will perform the pair-
wise comparison at individual medicine level (e.g. propranolol versus placebo), but if this is not feasible due to 
the number of studies, we will shift to drug class level (e.g. Beta blocking agents versus placebo), using the 
WHO's Anatomical Therapeutic Chemical (ATC) / Defined Daily Dose (DDD) Index 2019 as a reference 
(WHO2018). We will not perform a pair-wise meta-analysis in the case of comparisons with less than two 
contributing trials. 
Methods for network meta-analysis 
For primary outcomes, at both time points (3 months from trauma and at study endpoint), we will assess if there 
are sufficient data to perform a network meta-analysis. If there are sufficient data, we will perform a network 
meta-analysis using Markov Chain MonteCarlo methods. We will fit random-effects models in a Bayesian 
framework using WinBUGS/OpenBUGS (WinBUGS 2000), with standard code (Dias 2013a). 
 
The binomial likelihood will be used for dichotomous data and the normal likelihood for continuous data.  
 
We will assume a common between study heterogeneity variance for the relative treatment effects. Normal 
non-informative priors (0,100) will be used for trials baselines and treatment effects. Uni-form non-informative 
priors (0,5) for between trial SDs.  
 
We will assess convergence of three chains (using different initial values) based on visual inspection of history, 
Brooks-Gelman Rubin, and autocorrelation plots. If chains are judged to have converged, the preceding 
iterations will be discarded, and a further 50,000 iterations will be run. Estimates will be based on the latter 
iterations.  
We will report posterior medians with 95% credible intervals for all treatment effects, between-study standard 
deviations (to assess heterogeneity), and total residual deviance (to assess goodness off it). 
We will calculate the mean rank and probability of being most effective for each treatment (both with 95% 
credible intervals). 
 
We plan to perform the network meta-analysis at individual medicine level, but should this not be feasible we 
will also consider fit-ting models at drug class level using the WHO's ATC/DDD Index 2019as a reference (WHO 
2018), or including both individual medicine and drug class levels.  
 
We will assess the transitivity assumption (i.e. that effect modifiers are equally distributed across the 
comparisons) in several steps. First, we will assess the distribution of potential effect modifiers across treatment 
comparisons for the following study characteristics: year of publication, study setting, type of trauma, criteria 
for enrolling, age, gender, history of previous trauma of participants, time from traumatic event to treatment, 
period over which the treatment has been administered. Second, we will use standard methods to conduct a 
global assessment of inconsistency using WinBUGS/OpenBUGS (Dias 2013b;WinBUGS 2000).  
 
We will compare the goodness of fit of an inconsistency model with the network meta-analysis model used in 
the main analyses which assumes consistency between direct and indirect evidence. We will assess the impact 
on between-study SD (i.e. heterogeneity) and goodness of fit statistics (residual deviance and deviance 
information criterion (DIC)). 
 
Third, if there is sufficient evidence of potential inconsistency (e.g. improved fit of the inconsistency model of 5 
or more on the DIC, substantial reduction in between-study deviation), then we will fit node-splitting models 
(van Valkenhoef 2016), using the GraphicalMixed Treatments Comparisons (GeMTC) package in R (R 2017). 
 
Subgroup analysis and investigation of heterogeneity 
For both pairwise and network meta-analyses we will perform meta-regression analyses on primary outcomes 
only, to avoid the risk of identifying false positive findings through multiple testing. We plan to assess the impact 
on effectiveness of the following co-variates. 
•Setting (e.g. acute and emergency departments, surgery or in-tensive care survivors). 
•Interventions starting within 12 hours from trauma and interventions starting after 12 hours from trauma  
 
Sensitivity analysis  
We plan to investigate the impact of excluding studies at high risk of bias, defined by unclear allocation 
concealment or unblinded out-come assessment or uncertain unblinding of outcome assessment; the impact of 
using ITT data versus completer outcomes; and the impact of excluding cluster RCTs.  
 
To estimate the influence of small study effects on the network meta-analyses we will examine the association 
between effect estimates and their variance (small studies tend to have larger variances) for the primary 
outcomes (Dias 2010). We will asses the magnitude of the bias parameter along with its 95% credible intervals 
as well as the impact on relative effects estimates and between-trial standard deviation  
 
Summary of findings 
Direct treatment comparisons 
We will present the results of the meta-analysis using a 'Summary of findings' table for the pair-wise 
comparisons. The 'Summary offindings' table will include the following outcomes. 
•PTSD severity 
•Dropouts due to adverse events 
•PTSD rate 
•Functional disability 
•Quality of life 
We will use the five GRADE 'certainty assessment' domains (study design, risk of bias, inconsistency, 
indirectness, imprecision) to assess the certainty of the evidence in consideration of the studies that provided 
data for the specific outcome. We will use the GRADE-pro software (GRADEpro GDT 2015), and apply the 
methods and recommendations from the Cochrane Handbook for Systematic Re-views of Interventions, section 
11.5 (Higgins 2011). Grading will be assigned by at least two different review authors, disagreement will be 
resolved through discussion or if required by consulting a third review author (NM). We will use footnotes to 
justify the downgrading and upgrading of the evidence. We will note comments to aid the reader, when suitable. 
We will categorise the certainty of the evidence as high (further research is not likely to change our confience in 
the estimate of effect), moderate (further research is likely to have an important impact on the estimate of 
effect and may change it), low (further research is very likely to have an important impact on the estimate of 
effect and is likely to change it), or very low (estimate of effect is very uncertain). 
If we find that additional information regarding the outcome can-not be incorporated in the meta-analysis, we 
will report this in the comments and state whether this information supports or contradicts the meta-analysis 
results.  
Indirect and mixed comparisons  
We will create a ‘Summary of findings' table for the primary out-comes.  
We will use the five GRADE domains (study limitations, consistency of effect, imprecision, indirectness and 
publication bias) to assess the certainty of the evidence from the network meta-analysis, using the standard 
methods (Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011)),but with modifications to reflect specific issues in network meta-analysis. As proposed by Salanti 
2014, we will: 
•evaluate each piece of direct evidence in the network and classify it as either at low, moderate or high risk of 
bias, according to the usual GRADE guidelines; 
•for each pair-wise network estimate, we will consider the contribution of all direct estimates feeding into it, 
using the contributions matrix; 
•illustrate the ‘Risk of bias' assessments according to the contributions of each source of direct evidence to each 
network meta-analysis effect estimate. We will display this in a bar chart using green, yellow and red to 
represent low, moderate and high risk of bias, respectively; 
•for each pair-wise comparison, we will integrate the ‘Risk of bias' judgements and the respective contributions 
into a single judgement about study limitations and consider whether to down grade the quality of the evidence. 
We will assign numerical scores to each risk of bias judgement (e.g. 0 for low, −1 for moderate, and −2 for high 
risk of bias), and take a weighted average of these using the contribution of each direct estimate to the network 
estimates from the contributions matrix.  
 
We will use GRADEpro GDT and CINeMA software to generate data for the 'Summary of findings' tables (CINeMA 
2007; GRADEpro GDT2015), which will be presented according to Yepes-Nunez 2019, using placebo as 
comparator. We will justify all decisions to down-grade or upgrade the quality of the evidence using footnotes 
and make comments to aid the reader's understanding of the review, where necessary (Salanti 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
      
  
  
   
     
   
 
 
 
 
 
 
 
 
      
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
  
  
 
 
 
 
 


 
 
